<DOC>
	<DOCNO>NCT02224456</DOCNO>
	<brief_summary>Chronic Hepatitis B infection ( CHB ) know frequently identify cause liver disease predispose patient development hepatocellular carcinoma ( HCC ) . Active hepatitis B virus ( HBV ) replication key driver liver injury disease progression . Majority Chinese patient infect genotype B C HBV , different Caucasian counterpart . This prospective multi-center cohort open-label study design investigate long-term effect TDF prevention HCC disease progression well evaluate efficacy safety long-term TDF Chinese CHB subject advance liver disease . The study enrol 240 subject .</brief_summary>
	<brief_title>Efficacy Safety Study Tenofovir Disoproxil Fumarate ( TDF ) Chinese Chronic Hepatitis B ( CHB ) Subjects With Advanced Fibrosis &amp; Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 1860 year ( inclusive ) ; Presence HBsAg serum screen least 6 month screen assessment ; Serum HBV DNA &gt; =2000 IU/mL HBeAg positive screening ( without ALT elevation ) ; serum HBV DNA &gt; =200IU/mL HBeAg negative screening ( without ALT elevation ) ; Clinically diagnose advanced fibrosis compensate cirrhosis define follow : liver stiffness measure ( LSM ) &gt; 12.4 kiloPascals ( kpa ) ( ALT &gt; Upper limit normal [ ULN ] ) LSM &gt; 9.0 kpa ( ALT &lt; =ULN ) ; One following : Liver biopsy show advanced fibrosis cirrhosis ( Ishak score &gt; =4 , within previous 6 month screen provide treatment likely improve liver histology take since ) . The slide must available review independent histopathologist ; Endoscopyproven gastroesophageal gastric varix , noncirrhotic portal hypertension exclude ; Abdominal ultrasound CT find change indicate cirrhosis , irregular liver surface nodularity , with/without splenomegaly ( depth spleen &gt; 4.0cm spleen length &gt; 13cm ) ; Blood platelet &lt; 100 x10^9/L ( cause thrombocytopenia exclude ) ; Ability give write informed consent ; A female eligible enter participate study : nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) , Childbearing potential , negative urine pregnancy test screening , agree one follow method avoidance pregnancy period study 30 day last dose study medication : Oral contraceptive , either combined progestogen alone ; Injectable progestogen ; Implants levonorgestrel ; Oestrogenic vaginal ring ; Percutaneous contraceptive patch ; Intrauterine device ( IUD ) intrauterine system ( IUS ) show expected failure rate le 1 % per year state IUD IUS product label ; Has male partner sterilise ; Double barrier method : condom occlusive cap ( diaphragm orcervical/vault cap ) vaginal spermicidal agent ( foam/gel/film /cream/suppository ) . Agreement participate investigational trial undertake HBV systemic antiviral interferon ( IFN ) regimens participation study . Hepatocellular carcinoma evidence one following : Suspicious focus ultrasound radiological examination ; Normal ultrasound serum alphafetoprotein &gt; 50 nanogram ( ng ) /mL screen . Serum ALT &gt; 10 time ULN screen history acute exacerbation lead transient decompensation ; Documented coinfection hepatitis A ( HAV ) , hepatitis C ( HCV ) , hepatitis delta virus ( HDV ) , hepatitis E virus ( HEV ) human immunodeficiency virus ( HIV ) . For HCV coinfection , subject antiHCV positive HCV ribonucleic acid ( RNA ) undetectable consider eligible enrolment . Evidence active liver disease due autoimmune hepatitis ( antinuclear antibody ( ANA ) titre &gt; 1:160 ) . Decompensated liver disease indicate follow : serum bilirubin &gt; 1.5 xULN prothrombin time activity &lt; 60 % International normalize ratio ( INR ) &gt; 1.5 ; serum albumin &lt; 32 gram per liter ( g/L ) ; history previous clinical hepatic decompensation ( e.g. , ascites , variceal bleeding , encephalopathy ) ; Planned liver transplantation previous liver transplantation ; Creatinine clearance le 70 mL/minute ( min ) ; Haemoglobin &lt; 10 g/deciliter ( dL ) , white blood cell ( WBC ) count &lt; 1.5 x 10^9/liter ( L ) , platelets &lt; =50 x 10^9/L ; Any serious active medical psychiatric illness hepatitis B , opinion Investigator , would interfere subject treatment , assessment compliance protocol . This would include uncontrolled clinically significant renal , cardiac , pulmonary , vascular , neurogenic , digestive , metabolic ( diabetes , thyroid disorder , adrenal disease ) , immunodeficiency disorder , pathological fracture cancer ; Active alcohol drug abuse history alcohol drug abuse consider Investigator sufficient hinder compliance treatment , participation study interpretation result ; A female breastfeeding plan breastfeed ; Use immunosuppressive therapy , immunomodulatory therapy ( include IFN thymosin alpha ) , systemic cytotoxic agent , chronic antiviral agent include Chinese herbal medicine know activity HBV ( e.g. , lamivudine ( LAM ) , adefovir , entecavir ( ETV ) , telbivudine ( LdT ) hepatitis B immunoglobulin ( HBIg ) ) within previous 6 month prior screen study ; Have ever receive TDF medicinal product contain mentioned antiviral agent investigative antiHBV treatment ( e.g. , emtricitabine ( FTC ) , ( 2R,4R ) 4 ( 2,6Diaminopurin9yl ) 1,3dioxolan2yl ] methanol ( DAPD ) 1 ( 2fluoro5methylbeta , Larabinofuranosyl ) uracil ( LFMAU ) ) ; History hypersensitivity nucleoside and/or nucleotide analogues and/or component study medication ; Therapy nephrotoxic drug ( e.g. , aminoglycosides , amphotercin B , vancomycin , cidofovir , foscarnet , cisplatinum , pentamidine etc . ) competitor renal excretion ( e.g. , probenecid ) within 2 month prior study screen expectation subject receive course study ; Inability comply study requirement determine study Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>